希少疾病用医薬品指定の可能性がある成人がんおよび小児がんの治療法の開発に焦点を当てた臨床段階の治療薬会社であるQualigen Therapeutics, Inc.(NASDAQ:QLGN)は本日、第...
ログインすると全部閲覧できます。
ログイン
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan.
QN-302 works by selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may...
希少疾病用医薬品指定の可能性がある成人がんおよび小児がんの治療法の開発に焦点を当てた臨床段階の治療薬会社であるQualigen Therapeutics, Inc.(NASDAQ:QLGN)は本日、第...
ブラウザの共有ボタンを使って、このページを友人と共有することができます。